The medication is a tool, not a solution.
For decades, millions of Brazilians living with migraine have navigated a landscape of imperfect remedies — drugs that dulled pain without addressing its origins, or that carried risks for those with fragile hearts. On May 25, 2026, Brazil's health regulator Anvisa approved rimegepant, a molecule that interrupts migraine at its biological source by blocking the CGRP protein, offering both acute relief and prevention in a single treatment. The arrival of this gepant class marks not merely a new drug, but a shift in how medicine understands and addresses one of humanity's most disabling conditions — though the distance between scientific progress and those who most need it remains, as ever, a question of access and equity.
- Migraine affects millions of Brazilians and ranks as the second most disabling condition globally, yet a significant portion of sufferers have had no adequate treatment — triptans fail roughly 30% of patients and are outright dangerous for those with cardiovascular risk.
- Anvisa's approval of Nurtec ODT introduces rimegepant, the first gepant available in Brazil, capable of both stopping an attack in progress and preventing future ones — a dual function no prior migraine drug has offered in a single molecule.
- Clinical trial data from The Lancet shows 21% of patients were completely pain-free within two hours versus 11% on placebo, with additional relief from nausea, light sensitivity, and sound sensitivity, and a mild side-effect profile.
- Neurologists are urging caution: only 20–25% of patients achieve complete pain relief, and migraine management still demands sleep discipline, dietary awareness, stress control, and trigger identification alongside any medication.
- Neither pricing nor a launch date has been announced, and experts warn that the true measure of this breakthrough will be whether it reaches the patients who need it most — a challenge Brazil has yet to resolve.
Brazil's pharmaceutical regulator Anvisa approved a new migraine medication on May 25, 2026, clearing the way for a class of treatments that target migraine's biological mechanisms rather than simply suppressing symptoms after they emerge. The drug, Nurtec ODT, contains rimegepant — a molecule that blocks CGRP, a protein central to how pain signals travel and how inflammation builds during a migraine attack.
What distinguishes this approval is rimegepant's dual capability: depending on how it is prescribed, it can either halt a migraine already underway or prevent future attacks from occurring. It comes as orally dissolving 75-milligram tablets, though pricing and availability have not yet been announced.
Neurologist Dr. Danielle Calil describes the moment as a turning point. For years, triptans — which work by constricting blood vessels — were the standard acute treatment, but they fail about 30% of patients and pose real dangers for those with heart disease or stroke risk. Gepants bypass this problem entirely, blocking CGRP without affecting blood vessels and opening treatment to people previously left without good options.
The approval draws on phase 3 trial data published in The Lancet: 21% of patients taking a single 75-milligram dose were completely pain-free within two hours, compared to 11% on placebo, with additional relief from nausea and sensory sensitivity. Side effects were uncommon and mild.
Still, experts are measured in their optimism. Only 20–25% of patients achieve complete pain relief, and migraine remains a condition that demands lifestyle management — sleep, diet, stress, and trigger awareness — alongside any medication. The drug is a meaningful addition to the toolkit, not a cure.
The deeper question, Calil notes, is reach. CGRP was identified as a treatment target in the 1980s; it took decades to become a medicine. Now that gepants exist, the challenge shifts to whether they will actually arrive in the hands of the millions who need them. Migraine carries social stigma that keeps many from seeking help, and cost and access in Brazil remain entirely unresolved.
Brazil's health regulator has approved a new migraine medication that works through an entirely different mechanism than the drugs doctors have relied on for decades. The Anvisa, the country's pharmaceutical watchdog, registered Nurtec ODT on May 25, 2026, clearing the way for a class of treatments that target the biological root of migraine pain rather than simply dulling it after the fact. The active ingredient is rimegepant, a molecule that blocks CGRP, a protein central to how migraine pain signals travel through the nervous system and how inflammation builds during an attack.
What makes this approval significant is not just that another migraine drug has arrived in Brazil. It is that rimegepanto represents a fundamentally different approach—one that can both stop a migraine in progress and prevent future attacks from happening at all, depending on how a doctor prescribes it. The medication comes as orally dissolving tablets in 75-milligram doses, packaged in quantities of 2, 8, or 16 pills. Neither pricing nor a launch date has been announced yet.
Dr. Danielle Calil, a neurologist, frames this moment as a watershed in how migraine gets treated. For years, doctors have reached for triptans—drugs that work by constricting blood vessels—when patients came in during an acute attack. But roughly 30 percent of migraine sufferers do not respond adequately to triptans. Worse, the blood-vessel-constricting effect that makes triptans work can be dangerous for patients with heart disease or stroke risk. Gepants, as this new class is called, sidestep that problem entirely. They block CGRP without touching blood vessels, opening treatment options for people who were previously left with few choices.
The approval rests on clinical trial data published in The Lancet. In a phase 3 study, patients who took a single 75-milligram dose experienced meaningful pain relief and symptom improvement within two hours. Twenty-one percent of those treated with rimegepanto were completely pain-free in that window, compared to 11 percent of those given placebo. Beyond pain, patients also reported relief from nausea, light sensitivity, and sound sensitivity. The side effects most commonly reported—nausea and urinary tract infection—were uncommon and typically mild.
Yet Calil and other experts are careful to temper expectations. The trial results, while encouraging, do not mean that rimegepanto will cure migraine for most people. Only about 20 to 25 percent of patients achieve complete pain relief within two hours. The majority will see partial improvement or may need their treatment adjusted. Migraine, these doctors emphasize, remains a condition that demands more than a pill. Sleep, diet, stress management, and identifying personal triggers continue to matter as much as medication itself. The drug is a tool, not a solution.
The approval also highlights a larger scientific journey. CGRP was identified as a potential treatment target back in the 1980s, but the path from laboratory discovery to a drug a patient could actually take stretched across decades. Now, with gepants available for both acute and preventive use, and with monoclonal antibodies already approved for prevention, the toolkit for migraine management has expanded dramatically. The real test, Calil notes, will be whether these advances actually reach the people who need them. Migraine ranks as the second most disabling condition globally according to the World Health Organization, yet it carries a stigma that makes many sufferers reluctant to seek help. Cost and access in Brazil remain open questions.
Citas Notables
Gepants belong to a class designed specifically from understanding migraine's underlying biology. The central mechanism is blocking CGRP, a molecule with a fundamental role in pain transmission during an attack.— Dr. Danielle Calil, neurologist
Only about 20 to 25 percent of patients achieve complete pain relief within two hours. The majority will see partial improvement or may need treatment adjustments. Migraine remains a condition that demands more than a pill.— Dr. Danielle Calil
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this drug can both treat and prevent, rather than just one or the other?
Because most migraine patients live in a cycle—they get hit with an attack, they take something to stop it, then they wait for the next one. If you can use the same medication to interrupt an attack when it happens and also reduce how often attacks come, you've changed the entire relationship someone has with their disease. You're not just reactive anymore.
The source mentions that 30 percent of patients don't respond to triptans. That's a significant number. Why does that happen?
Triptans work by narrowing blood vessels, and that mechanism just doesn't work the same way in every person's brain. Some people's migraines don't involve the vascular component that triptans target. And for others, their bodies adapt over time. Rimegepanto works on a completely different pathway—the CGRP protein—so it can reach people triptans miss entirely.
The doctor says only 20 to 25 percent get complete pain relief. That sounds low. Why approve something with that success rate?
Because for someone who's been living with untreated migraines for years, even partial relief is transformative. And for the 20 to 25 percent who do get complete relief, it's life-changing. But you're right to notice the gap between the headline and the reality. That's why the doctor keeps saying lifestyle management still matters—the medication is one piece, not the whole answer.
What's the cardiovascular angle here? Why is that such a big deal?
Triptans constrict blood vessels. If you have heart disease or high stroke risk, that constriction could trigger a cardiac event. So doctors have to tell certain patients they can't use the most effective migraine treatment available. Rimegepanto doesn't constrict anything—it just blocks a pain signal. That opens the door for people who were previously locked out.
The source says cost and access are challenges. In Brazil specifically, what does that mean?
Brazil has a public health system, but it's stretched thin. A new, sophisticated drug like this will likely be expensive at first. It may end up available only to people who can pay privately, or it might take years to be added to public formularies. Meanwhile, the people who need it most—those with treatment-resistant migraines—are often those least able to afford it.
Why did it take so long to get from discovering CGRP in the 1980s to an actual drug?
Because understanding that a protein is involved in migraine is one thing. Actually designing a molecule that blocks it safely, testing it in thousands of people, proving it works better than placebo, and getting regulatory approval—that's a 30 to 40-year process. Science moves slowly when lives depend on getting it right.